MGEN Share Price | Viridian Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Viridian Therapeutics, Inc. do?

Overview: Viridian Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -87 Million (Quarterly Results - Mar 2025) Market-cap: USD 1,210.42 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.02 Return on Equity: -48.51% Price to Book: 2.00Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Viridian Therapeutics, Inc. overvalued or undervalued?

As of 13 November 2023, the valuation grade for Viridian Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently assessed as overvalued given its financial metrics, including a price-to-book value of 1.98, an EV to EBITDA ratio of -1.73, and a return on equity (ROE) of -48.51%. These ratios highlight the company's struggles, particularly as it operates at a loss and shows negative capital employed.In comparison to its peers, Viridian Therapeutics, Inc. stands out unfavorably against Innoviva, Inc. and Collegium Pharmaceutical, Inc., which have P/E ratios of 15.38 and 14.78, respectively. This stark contrast underscores the challenges Viridian faces in generating positive returns for investors. Furthermore, the company's stock has underperformed relative to the S&P 500, particularly year-to-date, where it has declined by 23.27% compared to the index's 2.44% gain. Overall, the combination of poor financial ratios and relative performance suggests that Viridian Therapeutics is overvalued in the current market environment.

Q: Is Viridian Therapeutics, Inc. technically bullish or bearish?

As of 26 August 2025, the technical trend for Viridian Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from Bollinger Bands and daily moving averages. The KST is also bullish on a weekly basis, while the Dow Theory indicates a mildly bullish stance. However, the OBV shows a mixed signal with a mildly bullish weekly reading but a mildly bearish monthly reading. In terms of performance, the stock has underperformed the S&P 500 over the 1Y and 3Y periods, with returns of -6.84% and -10.82% respectively, compared to the S&P 500's 17.14% and 70.41%. Over the 5Y period, the stock has outperformed with a return of 54.37% versus the S&P 500's 96.61%. Overall, the current technical stance is bullish, indicating a strengthening trend.

Results Declared: Viridian Therapeutics, Inc. has declared results on 05 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.93 M

Shareholding (Mar 2026)

FII

19.00%

Held by 110 FIIs

DII

34.23%

Held by 50 DIIs

Promoter

9.11%

How big is Viridian Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Viridian Therapeutics, Inc. has a market capitalization of 1,210.42 million and reported net sales of 0.30 million with a net profit of -293.24 million over the latest four quarters. Shareholder's funds are 671.64 million, and total assets amount to 742.40 million.

View full answer

What does Viridian Therapeutics, Inc. do?

22-Jun-2025

Viridian Therapeutics, Inc. is a micro-cap pharmaceutical and biotechnology company with no recent net sales and a net loss of $87 million as of March 2025. It has a market cap of approximately $1.21 billion and does not pay dividends.

View full answer

Is Viridian Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of November 13, 2023, Viridian Therapeutics, Inc. is considered overvalued and has been downgraded to "does not qualify" due to poor financial metrics and underperformance compared to peers and the S&P 500.

View full answer

Is Viridian Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 26, 2025, Viridian Therapeutics, Inc. shows a bullish technical trend, supported by positive indicators like the weekly MACD and Bollinger Bands, despite mixed performance signals and underperformance against the S&P 500 over the past 1Y and 3Y.

View full answer

Compare Viridian Therapeutics, Inc. with Similar Stocks

Amneal Pharmaceuticals, Inc.Arcturus Therapeutics Holdings, Inc.NewAmsterdam Pharma Co. NV

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Positive results in Sep 25

NET SALES(HY) At USD 70.64 MM has Grown at 44,612.03%
RAW MATERIAL COST(Y) Fallen by -134.62% (YoY)
OPERATING PROFIT(Q) Highest at USD -39.7 MM

Risky -

High Institutional Holdings at 100%

Market Beating Performance

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,940 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.93

Return on Equity

-57.04%

Price to Book

5.85

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Mar 2026)

Net Profit:

-105 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-41.88%

6 Months

-38.05%

1 Year

38.32%

2 Years

12.29%

3 Years

-35.36%

4 Years

66.99%

5 Years

-3.02%

Viridian Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

106.62%

EBIT Growth (5y)

-255.41%

EBIT to Interest (avg)

-106.87

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.85

EV to EBIT

-7.53

EV to EBITDA

-7.56

EV to Capital Employed

73.35

EV to Sales

34.91

PEG Ratio

Dividend Yield

ROCE (Latest)

-973.96%

ROE (Latest)

-57.04%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 54 Schemes (37.67%)

Foreign Institutions

Held by 110 Foreign Institutions (19.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -20.71% vs -79.18% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-116.00",
          "val2": "-93.50",
          "chgp": "-24.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.50",
          "val2": "0.60",
          "chgp": "483.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "7.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-104.90",
          "val2": "-86.90",
          "chgp": "-20.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-823,893.60%",
          "val2": "-1,303,694.40%",
          "chgp": "47,980.08%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 23,500.00% vs 0.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -35.14% vs 12.24% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "70.80",
          "val2": "0.30",
          "chgp": "23,500.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-362.20",
          "val2": "-297.80",
          "chgp": "-21.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.90",
          "val2": "3.00",
          "chgp": "63.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-281.90",
          "val2": "-208.60",
          "chgp": "-35.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,129.10%",
          "val2": "-990,182.10%",
          "chgp": "98,505.30%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.10

Operating Profit (PBDIT) excl Other Income

-116.00

-93.50

-24.06%

Interest

3.50

0.60

483.33%

Exceptional Items

7.50

0.00

Consolidate Net Profit

-104.90

-86.90

-20.71%

Operating Profit Margin (Excl OI)

-823,893.60%

-1,303,694.40%

47,980.08%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -20.71% vs -79.18% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

70.80

0.30

23,500.00%

Operating Profit (PBDIT) excl Other Income

-362.20

-297.80

-21.63%

Interest

4.90

3.00

63.33%

Exceptional Items

-0.70

0.00

Consolidate Net Profit

-281.90

-208.60

-35.14%

Operating Profit Margin (Excl OI)

-5,129.10%

-990,182.10%

98,505.30%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 23,500.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -35.14% vs 12.24% in Dec 2024

All Annual Results

Company CV

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available